Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes

By HospiMedica International staff writers
Posted on 14 May 2024

Over 37 million Americans are diagnosed with diabetes, and more than 90% of these cases are Type 2 diabetes. More...

This form of diabetes is most commonly seen in individuals over 45, though an increasing number of children, teenagers, and young adults are being diagnosed. Managing glucose can be costly with medications, and using insulin injections comes with side effects such as the risk of low blood sugar and weight gain. Now, an innovative procedure that involves the use of controlled electrical pulses to alter the lining of the first part of the small intestine could enable patients with Type 2 diabetes to discontinue insulin use while maintaining control of their blood glucose levels.

Previous research had studied the effects of ablating the small intestine's lining with heat, particularly after noting that patients undergoing gastric bypass surgery showed immediate improvements in insulin regulation post-operation, prior to any weight loss. This observation led researchers to propose that bypassing a specific part of the small intestine contributes to blood sugar management in Type 2 diabetes. It is theorized that prolonged exposure to a diet high in sugar and calories triggers an unidentified change in this intestinal segment, which in turn causes resistance to the body's insulin. Rejuvenating this intestinal tissue may enhance the body's responsiveness to its insulin, especially in Type 2 diabetes patients who still produce insulin naturally.

In a pioneering study conducted at the Amsterdam University Medical Center (Amsterdam, the Netherlands), 14 patients were treated with an endoscopic procedure that applied alternating electrical pulses to the duodenum—the section of the small intestine just below the stomach. This procedure lasted about an hour, after which patients were released the same day. They then followed a calorie-controlled liquid diet for two weeks. Subsequently, these patients started on semaglutide, a diabetes medication, gradually increasing the dose to 1 mg per week. While semaglutide alone typically enables roughly 20% of Type 2 diabetes patients to stop using insulin, in this study, 12 out of 14 patients, or 86%, successfully maintained optimal glycemic control without insulin for an entire year. This suggests that the improvements could be attributed to the new procedure rather than solely to the medication. Researchers are now initiating a double-blind randomized controlled trial to further investigate these findings.

“The potential for controlling diabetes with a single endoscopic treatment is spectacular,” said Celine Busch, the study’s lead researcher and PhD candidate in gastroenterology at Amsterdam University Medical Center. “One of the biggest advantages of this treatment is that a single outpatient endoscopic procedure provides glycemic control, a potential improvement over drug treatment, which depends on patients taking their medication day in, day out.”

Related Links:
Amsterdam UMC


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.